Evommune, Inc.·4

Nov 12, 4:22 PM ET

Pena Luis C. 4

4 · Evommune, Inc. · Filed Nov 12, 2025

Insider Transaction Report

Form 4
Period: 2025-11-07
Pena Luis C.
DirectorPresident & CEO
Transactions
  • Conversion

    Common Stock

    2025-11-07+24,225682,821 total
  • Conversion

    Series Seed Preferred Stock

    2025-11-07206,3550 total
    Common Stock (24,225 underlying)
Footnotes (1)
  • [F1]Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date.

Documents

1 file
  • 4
    form4-11122025_091154.xmlPrimary